Jurianz, K <br/><br/>
K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.  [electronic resource] 

 -  International journal of cancer  Sep 2001 
 - 848-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0020-7136 
<br/><br/><label>Standard No.: </label>10.1002/ijc.1406  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antigens, CD--immunology<br/>CD55 Antigens--immunology<br/>CD59 Antigens--immunology<br/>Cell Membrane--metabolism<br/>Complement Activation<br/>Complement System Proteins--immunology<br/>Dose-Response Relationship, Drug<br/>Enzyme Inhibitors--pharmacology<br/>Enzyme-Linked Immunosorbent Assay<br/>Erythrocytes--metabolism<br/>Flow Cytometry<br/>Humans<br/>K562 Cells<br/>Leukemia, Erythroblastic, Acute--immunology<br/>Membrane Cofactor Protein<br/>Membrane Glycoproteins--immunology<br/>Naphthalenes--pharmacology<br/>Neutrophils--metabolism<br/>Plant Proteins--pharmacology<br/>Protein Kinase C--metabolism<br/>Signal Transduction<br/>Tetradecanoylphorbol Acetate--pharmacology<br/>Trypsin Inhibitors<br/>Tumor Necrosis Factor-alpha--pharmacology<br/>alpha-Amylases--antagonists & inhibitors